A citation-based method for searching scientific literature

J Randolph Hecht, Yung-Jue Bang, Shukui K Qin, Hyun C Chung, Jianming M Xu, Joon O Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M Hoff, Alberto Sobrero, Pamela Salman, Jin Li, Svetlana A Protsenko, Zev A Wainberg, Marc Buyse, Karen Afenjar, Vincent Houé, Agathe Garcia, Tomomi Kaneko, Yingjie Huang, Saba Khan-Wasti, Sergio Santillana, Michael F Press, Dennis Slamon. J Clin Oncol 2016
Times Cited: 341







List of co-cited articles
799 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
82

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Karen Cheng, Chunyan Song, Haiyan Wu, Jennifer Eng-Wong, Katherine Kim,[...]. Lancet Oncol 2018
182
65

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara,[...]. Lancet Oncol 2017
227
58

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Taroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, Guo-Ping Sun, Toshihiko Doi, Jian-Ming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jin-Wan Wang,[...]. J Clin Oncol 2014
390
56

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee,[...]. N Engl J Med 2020
240
46

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae-You Kim,[...]. Lancet Oncol 2014
44



Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Charles S Fuchs, Jiri Tomasek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira Dos Santos, Giuseppe Aprile, David R Ferry,[...]. Lancet 2014
37

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Charles S Fuchs, Toshihiko Doi, Raymond W Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I Jalal, Manish A Shah, Jean-Phillipe Metges,[...]. JAMA Oncol 2018
834
31

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
30

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Tom Waddell, Ian Chau, David Cunningham, David Gonzalez, Alicia Frances Clare Okines, Clare Okines, Andrew Wotherspoon, Claire Saffery, Gary Middleton, Jonathan Wadsley,[...]. Lancet Oncol 2013
502
28

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Kohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun C Chung,[...]. Lancet 2018
599
28

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Florian Lordick, Yoon-Koo Kang, Hyun-Cheol Chung, Pamela Salman, Sang Cheul Oh, György Bodoky, Galina Kurteva, Constantin Volovat, Vladimir M Moiseyenko, Vera Gorbunova,[...]. Lancet Oncol 2013
582
27

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada, Junji Kawada, Ayumu Hosokawa, Yoshiki Horie, Akihito Tsuji, Toshikazu Moriwaki, Hiroaki Tanioka, Katsunori Shinozaki,[...]. J Clin Oncol 2020
50
54

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko,[...]. Lancet Oncol 2017
176
24

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Eric Van Cutsem, Yung-Jue Bang, Feng Feng-Yi, Jian M Xu, Keun-Wook Lee, Shun-Chang Jiao, Jorge León Chong, Roberto I López-Sanchez, Timothy Price, Oleg Gladkov,[...]. Gastric Cancer 2015
242
24

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Yelena Y Janjigian, Steven B Maron, Walid K Chatila, Brittanie Millang, Shweta S Chavan, Carly Alterman, Joanne F Chou, Michal F Segal, Marc Z Simmons, Parisa Momtaz,[...]. Lancet Oncol 2020
102
24

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Atsushi Ohtsu, Manish A Shah, Eric Van Cutsem, Sun Young Rha, Akira Sawaki, Sook Ryun Park, Ho Yeong Lim, Yasuhide Yamada, Jian Wu, Bernd Langer,[...]. J Clin Oncol 2011
799
23

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
Manish A Shah, Yung-Jue Bang, Florian Lordick, Maria Alsina, Meng Chen, Stephen P Hack, Jean Marie Bruey, Dustin Smith, Ian McCaffery, David S Shames,[...]. JAMA Oncol 2017
152
23

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
E C Smyth, M Verheij, W Allum, D Cunningham, A Cervantes, D Arnold. Ann Oncol 2016
756
22

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kohei Shitara, Toshihiko Doi, Mikhail Dvorkin, Wasat Mansoor, Hendrik-Tobias Arkenau, Aliaksandr Prokharau, Maria Alsina, Michele Ghidini, Catia Faustino, Vera Gorbunova,[...]. Lancet Oncol 2018
195
22

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, Charles Fuchs, Lucjan Wyrwicz, Keun-Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee,[...]. JAMA Oncol 2020
188
22

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Kohei Shitara, Hiroji Iwata, Shunji Takahashi, Kenji Tamura, Haeseong Park, Shanu Modi, Junji Tsurutani, Shigenori Kadowaki, Kensei Yamaguchi, Satoru Iwasa,[...]. Lancet Oncol 2019
95
21

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
20

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Jin Li, Shukui Qin, Jianming Xu, Jianping Xiong, Changping Wu, Yuxian Bai, Wei Liu, Jiandong Tong, Yunpeng Liu, Ruihua Xu,[...]. J Clin Oncol 2016
536
19

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Daniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, Hope E Uronis, Keun-Wook Lee, Matthew C H Ng, Peter C Enzinger, Se Hoon Park, Philip J Gold, Jill Lacy,[...]. Lancet Oncol 2020
58
32

Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
M Hofmann, O Stoss, D Shi, R Büttner, M van de Vijver, W Kim, A Ochiai, J Rüschoff, T Henkel. Histopathology 2008
805
18

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Toshihiko Doi, Kohei Shitara, Yoichi Naito, Akihiko Shimomura, Yasuhiro Fujiwara, Kan Yonemori, Chikako Shimizu, Tatsunori Shimoi, Yasutoshi Kuboki, Nobuaki Matsubara,[...]. Lancet Oncol 2017
171
18



Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.
Yelena Y Janjigian, Francisco Sanchez-Vega, Philip Jonsson, Walid K Chatila, Jaclyn F Hechtman, Geoffrey Y Ku, Jamie C Riches, Yaelle Tuvy, Ritika Kundra, Nancy Bouvier,[...]. Cancer Discov 2018
169
18

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Yung-Jue Bang, Rui-Hua Xu, Keisho Chin, Keun-Wook Lee, Se Hoon Park, Sun Young Rha, Lin Shen, Shukui Qin, Nong Xu, Seock-Ah Im,[...]. Lancet Oncol 2017
164
17

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi, Chiaki Ishii, Naoya Harada, Masako Soma, Hiromi Okamoto, Masataka Oitate, Shingo Arakawa,[...]. Clin Cancer Res 2016
278
17


Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.
Razvan Cristescu, Jeeyun Lee, Michael Nebozhyn, Kyoung-Mee Kim, Jason C Ting, Swee Seong Wong, Jiangang Liu, Yong Gang Yue, Jian Wang, Kun Yu,[...]. Nat Med 2015
983
16

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.
Seung Tae Kim, Razvan Cristescu, Adam J Bass, Kyoung-Mee Kim, Justin I Odegaard, Kyung Kim, Xiao Qiao Liu, Xinwei Sher, Hun Jung, Mijin Lee,[...]. Nat Med 2018
558
16


First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli,[...]. Lancet 2021
187
16


Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
David Cunningham, William H Allum, Sally P Stenning, Jeremy N Thompson, Cornelis J H Van de Velde, Marianne Nicolson, J Howard Scarffe, Fiona J Lofts, Stephen J Falk, Timothy J Iveson,[...]. N Engl J Med 2006
15

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Charles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, Sara Lonardi, Salah-Eddin Al-Batran, Eric Van Cutsem, David H Ilson, Maria Alsina, Ian Chau, Jill Lacy,[...]. Lancet Oncol 2019
104
15

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
Atsushi Ohtsu, Jaffer A Ajani, Yu-Xian Bai, Yung-Jue Bang, Hyun-Cheol Chung, Hong-Ming Pan, Tarek Sahmoud, Lin Shen, Kun-Huei Yeh, Keisho Chin,[...]. J Clin Oncol 2013
342
14

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Hugo E R Ford, Andrea Marshall, John A Bridgewater, Tobias Janowitz, Fareeda Y Coxon, Jonathan Wadsley, Wasat Mansoor, David Fyfe, Srinivasan Madhusudan, Gary W Middleton,[...]. Lancet Oncol 2014
366
13

Capecitabine and oxaliplatin for advanced esophagogastric cancer.
David Cunningham, Naureen Starling, Sheela Rao, Timothy Iveson, Marianne Nicolson, Fareeda Coxon, Gary Middleton, Francis Daniel, Jacqueline Oates, Andrew Richard Norman. N Engl J Med 2008
13

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Lin Shen, Jin Li, Jianming Xu, Hongming Pan, Guanghai Dai, Shukui Qin, Liwei Wang, Jinwan Wang, Zhenzhou Yang, Yongqian Shu,[...]. Gastric Cancer 2015
165
13

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Morihito Okada, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki,[...]. Lancet Oncol 2019
342
13

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.
Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, Geoffrey Y Ku, Yaelle Tuvy, Helen Won, Christopher J Fong, Nancy Bouvier, Gouri J Nanjangud, Joanne Soong,[...]. Cancer Discov 2019
76
17

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.
M Tanner, M Hollmén, T T Junttila, A I Kapanen, S Tommola, Y Soini, H Helin, J Salo, H Joensuu, E Sihvo,[...]. Ann Oncol 2005
517
13

A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
E Van Cutsem, Y-J Bang, W Mansoor, R D Petty, Y Chao, D Cunningham, D R Ferry, N R Smith, P Frewer, J Ratnayake,[...]. Ann Oncol 2017
105
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.